Is Indaptus Therapeutics, Inc. (INDP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.0% / 30% | 139.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 2.0% / 33% | 139.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.1% / 33% | 78.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.0% / 33% | 139.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.1% / 33% | 78.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -587.6% | |
| Return on Assets (ROA) | -148.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$12M |
| Free Cash Flow | -$12M |
| Total Debt | $84,164 |
| Current Ratio | 1.5 |
| Total Assets | $7M |
Price & Trading
| Last Close | $1.78 |
| 50-Day MA | $2.02 |
| 200-Day MA | $4.52 |
| Avg Volume | 649K |
| Beta | 1.0 |
|
52-Week Range
$1.52
| |
About Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Indaptus Therapeutics, Inc. (INDP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Indaptus Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Indaptus Therapeutics, Inc.'s debt ratio?
Indaptus Therapeutics, Inc.'s debt ratio is 2.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are Indaptus Therapeutics, Inc.'s key financial metrics?
Indaptus Therapeutics, Inc. has a market capitalization of $4M. Return on equity stands at -587.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.